|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
NLM33021330X |
| 003 |
DE-627 |
| 005 |
20240909232010.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231225s2021 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2021.108845
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1528.xml
|
| 035 |
|
|
|a (DE-627)NLM33021330X
|
| 035 |
|
|
|a (NLM)34478882
|
| 035 |
|
|
|a (PII)S1521-6616(21)00182-0
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Ramirez, Giuseppe A
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Impact of the COVID-19 pandemic in patients with systemic lupus erythematosus throughout one year
|
| 264 |
|
1 |
|c 2021
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 13.10.2021
|
| 500 |
|
|
|a Date Revised 08.09.2024
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2021 Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a Little is known about the impact of coronavirus disease 2019 (COVID-19) pandemic to the care of patients with systemic lupus erythematosus (SLE) in the long-term. By crossing population data with the results of a web-based survey focused on the timeframes January-April and May-December 2020, we found that among 334/518 responders, 28 had COVID-19 in 2020. Seventeen cases occurred in May-December, in parallel with trends in the general population and loosening of containment policy strength. Age > 40 years (p = 0.026), prednisone escalation (p = 0.008) and infected relatives (p < 0.001) were most significantly associated with COVID-19. Weaker associations were found with asthma, lymphadenopathy and azathioprine or cyclosporine treatment. Only 31% of patients with infected relatives developed COVID-19. Healthcare service disruptions were not associated with rising hospitalisations. Vaccination prospects were generally welcomed. Our data suggest that COVID-19 has a moderate impact on patients with SLE, which might be significantly modulated by public health policies, including vaccination
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a COVID-19
|
| 650 |
|
4 |
|a Containment
|
| 650 |
|
4 |
|a Coronavirus
|
| 650 |
|
4 |
|a Lockdown
|
| 650 |
|
4 |
|a Prednisone
|
| 650 |
|
4 |
|a Public health
|
| 650 |
|
4 |
|a Systemic lupus erythematosus
|
| 650 |
|
4 |
|a Treatment
|
| 650 |
|
4 |
|a Vaccination
|
| 650 |
|
7 |
|a COVID-19 Vaccines
|2 NLM
|
| 650 |
|
7 |
|a Immunosuppressive Agents
|2 NLM
|
| 700 |
1 |
|
|a Argolini, Lorenza M
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Bellocchi, Chiara
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Moroni, Luca
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Della-Torre, Emanuel
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Farina, Nicola
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Caporali, Roberto F
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Beretta, Lorenzo
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Gerosa, Maria
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Bozzolo, Enrica P
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Dagna, Lorenzo
|e verfasserin
|4 aut
|
| 700 |
0 |
|
|a SMILE, Milan Lupus Consortium
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 231(2021) vom: 07. Okt., Seite 108845
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:231
|g year:2021
|g day:07
|g month:10
|g pages:108845
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2021.108845
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 231
|j 2021
|b 07
|c 10
|h 108845
|